- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01743989
A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. (ENESTPath)
A Prospective, Randomized, Open Label, Two Arm Phase III Study to Evaluate Treatment Free Remission (TFR) Rate in Patients With Philadelphia-positive CML After Two Different Durations of Consolidation Treatment With Nilotinib 300mg BID.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a prospective, randomized, open-label, multicenter Phase III study. The study design was made up of 3 phases:
- Nilotinib induction phase: 12 months
- Nilotinib consolidation phase: 12 or 24 months, depending on randomization
- Nilotinib treatment-free remission (TFR) phase: 24 or 36 months, depending on randomization.
Subjects were enrolled into the study and were treated with nilotinib 300mg twice daily (BID) for 24 months, during the induction (12 months) and consolidation (12 months) phases. At the end of the first 24 months of treatment, participants achieving a sustained molecular response (defined as ≥ MR4.0, in 4 out of 5 real-time quantitative polymerase chain reaction (RQ-PCR) assessments, including the last assessment, in the last 12 months) were randomized on a 1:1 basis to either:
- suspend nilotinib treatment immediately and enter the TFR phase for 36 months (Nilotinib 24-month treatment arm), or
- continue nilotinib treatment for a further 12 months (post-randomization consolidation phase), then suspend treatment and enter the TFR phase for 24 months (Nilotinib 36-month treatment arm).
Participants not achieving a sustained molecular response at 24 months from treatment start were not eligible for randomization and were treated at the discretion of the investigator according to standard practice. Information on survival, stem cell transplantation, and status of the patient's disease was collected until death or until 5 years from study entry, whichever came first. Additionally, for Nilotinib 36-month treatment arm, participants who did not achieve a sustained molecular response at 36 months from treatment start, discontinued from the study and were treated according to standard practice and followed up until death or until 5 years from study entry, whichever came first.
Participants relapsing during the TFR phase entered the nilotinib re-treatment phase of the study, and were re-treated with the same dose of nilotinib as they were on before the TFR phase. These patients remained on study until the completion of the 5-year study period unless prematurely withdrawn and discontinued from the study for any reason specified in the Protocol.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Graz, Austria, 8036
- Novartis Investigative Site
-
Linz, Austria, A-4010
- Novartis Investigative Site
-
Linz, Austria, 4010
- Novartis Investigative Site
-
Rankweil, Austria, A-6830
- Novartis Investigative Site
-
Salzburg, Austria, 5020
- Novartis Investigative Site
-
-
Oberoesterreich
-
Linz, Oberoesterreich, Austria, A 4020
- Novartis Investigative Site
-
-
-
-
-
Bruxelles, Belgium, 1070
- Novartis Investigative Site
-
Liege, Belgium, 4000
- Novartis Investigative Site
-
-
-
-
-
Pleven, Bulgaria, 5800
- Novartis Investigative Site
-
Plovdiv, Bulgaria, 4002
- Novartis Investigative Site
-
Sofia, Bulgaria, 1756
- Novartis Investigative Site
-
Sofia, Bulgaria, 1431
- Novartis Investigative Site
-
Varna, Bulgaria, 9000
- Novartis Investigative Site
-
-
-
-
CZE
-
Hradec Kralove, CZE, Czechia, 500 05
- Novartis Investigative Site
-
-
Czech Republic
-
Brno Bohunice, Czech Republic, Czechia, 625 00
- Novartis Investigative Site
-
-
-
-
-
Holstebro, Denmark, DK-7500
- Novartis Investigative Site
-
Roskilde, Denmark, 4000
- Novartis Investigative Site
-
-
-
-
-
HUS Helsinki, Finland, FIN-00029
- Novartis Investigative Site
-
-
-
-
-
Angers Cedex 1, France, 49033
- Novartis Investigative Site
-
Bordeaux, France, 33076
- Novartis Investigative Site
-
Bordeaux Cedex, France, 33000
- Novartis Investigative Site
-
Chalon sur Saône, France, 71321
- Novartis Investigative Site
-
Chambéry cedex, France, 73011
- Novartis Investigative Site
-
Clermont Ferrand cedex 1, France, 63003
- Novartis Investigative Site
-
Corbeil Essonnes, France, 91100
- Novartis Investigative Site
-
Dunkerque, France, 59240
- Novartis Investigative Site
-
Grenoble, France, 38043
- Novartis Investigative Site
-
La Roche sur Yon cedex 9, France, 85925
- Novartis Investigative Site
-
Lille, France, 59037
- Novartis Investigative Site
-
Lille cedex, France, 59020
- Novartis Investigative Site
-
Lyon Cedex, France, 69373
- Novartis Investigative Site
-
Marseille, France, 13273
- Novartis Investigative Site
-
Metz, France, 57085
- Novartis Investigative Site
-
Metz, France, 57000
- Novartis Investigative Site
-
Mulhouse cedex, France, 68070
- Novartis Investigative Site
-
Nice Cedex, France, 06202
- Novartis Investigative Site
-
Paris, France, 75012
- Novartis Investigative Site
-
Perpignan, France, 66046
- Novartis Investigative Site
-
Pontoise, France, F-95300
- Novartis Investigative Site
-
Rouen Cedex 1, France, 76038
- Novartis Investigative Site
-
Saint Priest en Jarez, France, 42271
- Novartis Investigative Site
-
Toulouse, France, 31059
- Novartis Investigative Site
-
-
Bayonne Cedex
-
Bayonne, Bayonne Cedex, France, 64109
- Novartis Investigative Site
-
-
Cedex
-
Caen, Cedex, France, 14033
- Novartis Investigative Site
-
-
Cedex 09
-
Le Mans, Cedex 09, France, 72037
- Novartis Investigative Site
-
-
Cedex 10
-
Paris Cedex 10, Cedex 10, France, 75475
- Novartis Investigative Site
-
-
-
-
-
Augsburg, Germany, 86150
- Novartis Investigative Site
-
Bayreuth, Germany, 95445
- Novartis Investigative Site
-
Berlin, Germany, 13353
- Novartis Investigative Site
-
Braunschweig, Germany, 38114
- Novartis Investigative Site
-
Bremen, Germany, 28177
- Novartis Investigative Site
-
Chemnitz, Germany, 09113
- Novartis Investigative Site
-
Dresden, Germany, 01307
- Novartis Investigative Site
-
Eisenach, Germany, 99817
- Novartis Investigative Site
-
Frankfurt, Germany, 60596
- Novartis Investigative Site
-
Georgsmarienhuette, Germany, 49124
- Novartis Investigative Site
-
Halle, Germany, 06110
- Novartis Investigative Site
-
Hamm, Germany, 59063
- Novartis Investigative Site
-
Kiel, Germany, 24105
- Novartis Investigative Site
-
Koeln, Germany, 50671
- Novartis Investigative Site
-
Leipzig, Germany, 04103
- Novartis Investigative Site
-
Lütten-Klein, Germany, 18107
- Novartis Investigative Site
-
Magdeburg, Germany, 39104
- Novartis Investigative Site
-
Marburg, Germany, 35039
- Novartis Investigative Site
-
Muenchen, Germany, 81241
- Novartis Investigative Site
-
Muenster, Germany, 48149
- Novartis Investigative Site
-
Nuernberg, Germany, 90449
- Novartis Investigative Site
-
Offenburg, Germany, 77654
- Novartis Investigative Site
-
Potsdam, Germany, 14467
- Novartis Investigative Site
-
Rostock, Germany, 18057
- Novartis Investigative Site
-
Rostock, Germany, 18059
- Novartis Investigative Site
-
Schorndorf, Germany, 73614
- Novartis Investigative Site
-
Schwäbisch-Hall, Germany, 74523
- Novartis Investigative Site
-
Stuttgart, Germany, 70174
- Novartis Investigative Site
-
Velbert, Germany, 42551
- Novartis Investigative Site
-
Westerstede, Germany, 26655
- Novartis Investigative Site
-
Wiesbaden, Germany, 65191
- Novartis Investigative Site
-
Wuerzburg, Germany, 97080
- Novartis Investigative Site
-
-
Baden-Wuerttemberg
-
Mannheim, Baden-Wuerttemberg, Germany, 68305
- Novartis Investigative Site
-
-
-
-
-
Athens, Greece, 115 27
- Novartis Investigative Site
-
Athens, Greece, 106 76
- Novartis Investigative Site
-
Patras, Greece, 265 00
- Novartis Investigative Site
-
-
GR
-
Athens, GR, Greece, 115 27
- Novartis Investigative Site
-
Thessaloniki, GR, Greece, 570 10
- Novartis Investigative Site
-
-
-
-
-
Budapest, Hungary, 1097
- Novartis Investigative Site
-
Debrecen, Hungary, 4032
- Novartis Investigative Site
-
Szeged, Hungary, H 6725
- Novartis Investigative Site
-
-
-
-
-
Napoli, Italy, 80131
- Novartis Investigative Site
-
Novara, Italy, 28100
- Novartis Investigative Site
-
Perugia, Italy, 06129
- Novartis Investigative Site
-
-
AL
-
Alessandria, AL, Italy, 15100
- Novartis Investigative Site
-
-
AN
-
Ancona, AN, Italy, 60126
- Novartis Investigative Site
-
-
AV
-
Avellino, AV, Italy, 83100
- Novartis Investigative Site
-
-
BA
-
Bari, BA, Italy, 70124
- Novartis Investigative Site
-
-
BO
-
Bologna, BO, Italy, 40138
- Novartis Investigative Site
-
-
BS
-
Brescia, BS, Italy, 25123
- Novartis Investigative Site
-
-
CA
-
Cagliari, CA, Italy, 09126
- Novartis Investigative Site
-
-
CR
-
Cremona, CR, Italy, 26100
- Novartis Investigative Site
-
-
CT
-
Catania, CT, Italy, 95100
- Novartis Investigative Site
-
-
FE
-
Cona, FE, Italy, 44100
- Novartis Investigative Site
-
-
FG
-
San Giovanni Rotondo, FG, Italy, 71013
- Novartis Investigative Site
-
-
FI
-
Firenze, FI, Italy, 50134
- Novartis Investigative Site
-
-
GE
-
Genova, GE, Italy, 16132
- Novartis Investigative Site
-
-
LE
-
Lecce, LE, Italy, 73100
- Novartis Investigative Site
-
-
LI
-
Livorno, LI, Italy, 57124
- Novartis Investigative Site
-
-
Lazio
-
Roma, Lazio, Italy, 00168
- Novartis Investigative Site
-
-
ME
-
Messina, ME, Italy, 98125
- Novartis Investigative Site
-
-
MI
-
Milano, MI, Italy, 20162
- Novartis Investigative Site
-
Milano, MI, Italy, 20132
- Novartis Investigative Site
-
Milano, MI, Italy, 20122
- Novartis Investigative Site
-
-
MO
-
Modena, MO, Italy, 41124
- Novartis Investigative Site
-
-
PA
-
Palermo, PA, Italy, 90127
- Novartis Investigative Site
-
Palermo, PA, Italy, 90146
- Novartis Investigative Site
-
-
PD
-
Padova, PD, Italy, 35128
- Novartis Investigative Site
-
-
PE
-
Pescara, PE, Italy, 65124
- Novartis Investigative Site
-
-
PI
-
Pisa, PI, Italy, 56126
- Novartis Investigative Site
-
-
PR
-
Parma, PR, Italy, 43100
- Novartis Investigative Site
-
-
PV
-
Pavia, PV, Italy, 27100
- Novartis Investigative Site
-
-
PZ
-
Potenza, PZ, Italy, 85100
- Novartis Investigative Site
-
-
RC
-
Reggio Calabria, RC, Italy, 89124
- Novartis Investigative Site
-
-
RE
-
Reggio Emilia, RE, Italy, 42123
- Novartis Investigative Site
-
-
RM
-
Roma, RM, Italy, 00144
- Novartis Investigative Site
-
Roma, RM, Italy, 00161
- Novartis Investigative Site
-
Roma, RM, Italy, 00133
- Novartis Investigative Site
-
-
SA
-
Pagani, SA, Italy, 84016
- Novartis Investigative Site
-
-
SI
-
Siena, SI, Italy, 53100
- Novartis Investigative Site
-
-
TA
-
Taranto, TA, Italy, 74100
- Novartis Investigative Site
-
-
TO
-
Orbassano, TO, Italy, 10043
- Novartis Investigative Site
-
Torino, TO, Italy, 10126
- Novartis Investigative Site
-
-
TV
-
Treviso, TV, Italy, 31100
- Novartis Investigative Site
-
-
UD
-
Udine, UD, Italy, 33100
- Novartis Investigative Site
-
-
VE
-
Mirano, VE, Italy, 30035
- Novartis Investigative Site
-
Venezia, VE, Italy, 30174
- Novartis Investigative Site
-
-
VI
-
Vicenza, VI, Italy, 36100
- Novartis Investigative Site
-
-
VR
-
Verona, VR, Italy, 37126
- Novartis Investigative Site
-
-
-
-
-
Bergen, Norway, NO-5021
- Novartis Investigative Site
-
Oslo, Norway, NO-0310
- Novartis Investigative Site
-
-
-
-
-
Chorzow, Poland, 41-500
- Novartis Investigative Site
-
Gdansk, Poland, 80 952
- Novartis Investigative Site
-
Katowice, Poland, 40-027
- Novartis Investigative Site
-
Krakow, Poland, 30-510
- Novartis Investigative Site
-
Olsztyn, Poland, 10 561
- Novartis Investigative Site
-
Opole, Poland, 45-372
- Novartis Investigative Site
-
Torun, Poland, 87 100
- Novartis Investigative Site
-
Warszawa, Poland, 02 776
- Novartis Investigative Site
-
Warszawa, Poland, 02 106
- Novartis Investigative Site
-
-
-
-
-
Lisboa, Portugal, 1749-035
- Novartis Investigative Site
-
Lisboa, Portugal, 1099 023
- Novartis Investigative Site
-
Porto, Portugal, 4099-001
- Novartis Investigative Site
-
Porto, Portugal, 4200-072
- Novartis Investigative Site
-
Porto, Portugal, 4200 319
- Novartis Investigative Site
-
-
-
-
-
Bucharest, Romania, 030 171
- Novartis Investigative Site
-
Bucharest, Romania, 500098
- Novartis Investigative Site
-
Cluj-Napoca, Romania, 400124
- Novartis Investigative Site
-
Iasi, Romania, 700483
- Novartis Investigative Site
-
Sibiu, Romania, 550245
- Novartis Investigative Site
-
Timisoara, Romania, 300 079
- Novartis Investigative Site
-
-
District 2
-
Bucharest, District 2, Romania, 022328
- Novartis Investigative Site
-
-
-
-
-
Belgrade, Serbia, 11000
- Novartis Investigative Site
-
Belgrade, Serbia, 11070
- Novartis Investigative Site
-
Nis, Serbia, 18000
- Novartis Investigative Site
-
Novi Sad, Serbia
- Novartis Investigative Site
-
-
-
-
-
Bratislava, Slovakia, 85107
- Novartis Investigative Site
-
Martin, Slovakia, 03601
- Novartis Investigative Site
-
-
-
-
-
Ljubljana, Slovenia, 1000
- Novartis Investigative Site
-
-
-
-
-
Granollers, Spain, 08402
- Novartis Investigative Site
-
Madrid, Spain, 28041
- Novartis Investigative Site
-
Madrid, Spain, 28034
- Novartis Investigative Site
-
Madrid, Spain, 28046
- Novartis Investigative Site
-
Madrid, Spain, 28006
- Novartis Investigative Site
-
Madrid, Spain, 28040
- Novartis Investigative Site
-
Madrid, Spain, 28009
- Novartis Investigative Site
-
Madrid, Spain, 28222
- Novartis Investigative Site
-
Madrid, Spain, 28031
- Novartis Investigative Site
-
Murcia, Spain, 30008
- Novartis Investigative Site
-
Santa Cruz de Tenerife, Spain, 38009
- Novartis Investigative Site
-
Zaragoza, Spain, 50009
- Novartis Investigative Site
-
-
Andalucia
-
Granada, Andalucia, Spain, 18014
- Novartis Investigative Site
-
Jaen, Andalucia, Spain, 23007
- Novartis Investigative Site
-
Malaga, Andalucia, Spain, 29010
- Novartis Investigative Site
-
Sevilla, Andalucia, Spain, 41013
- Novartis Investigative Site
-
Sevilla, Andalucia, Spain, 41009
- Novartis Investigative Site
-
-
Barcelona
-
Sabadell, Barcelona, Spain, 08208
- Novartis Investigative Site
-
-
Castilla Y Leon
-
León, Castilla Y Leon, Spain, 24071
- Novartis Investigative Site
-
Salamanca, Castilla Y Leon, Spain, 37007
- Novartis Investigative Site
-
Valladolid, Castilla Y Leon, Spain, 47011
- Novartis Investigative Site
-
-
Catalunya
-
Badalona, Catalunya, Spain, 08916
- Novartis Investigative Site
-
Barcelona, Catalunya, Spain, 08035
- Novartis Investigative Site
-
Barcelona, Catalunya, Spain, 08036
- Novartis Investigative Site
-
Barcelona, Catalunya, Spain, 08003
- Novartis Investigative Site
-
Girona, Catalunya, Spain, 17007
- Novartis Investigative Site
-
Hospitalet de LLobregat, Catalunya, Spain, 08907
- Novartis Investigative Site
-
Tarragona, Catalunya, Spain, 43005
- Novartis Investigative Site
-
-
Comunidad Valenciana
-
Alicante, Comunidad Valenciana, Spain, 03010
- Novartis Investigative Site
-
Alzira, Comunidad Valenciana, Spain, 46600
- Novartis Investigative Site
-
Valencia, Comunidad Valenciana, Spain, 46026
- Novartis Investigative Site
-
-
Extremadura
-
Caceres, Extremadura, Spain, 10003
- Novartis Investigative Site
-
-
Galicia
-
La Coruna, Galicia, Spain, 15006
- Novartis Investigative Site
-
Pontevedra, Galicia, Spain, 36071
- Novartis Investigative Site
-
Santiago de Compostela, Galicia, Spain, 15706
- Novartis Investigative Site
-
-
Islas Baleares
-
Palma De Mallorca, Islas Baleares, Spain, 07120
- Novartis Investigative Site
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Novartis Investigative Site
-
-
Pais Vasco
-
San Sebastian, Pais Vasco, Spain, 20080
- Novartis Investigative Site
-
-
-
-
-
Stockholm, Sweden, SE-171 76
- Novartis Investigative Site
-
-
-
-
-
East Yorkshire, United Kingdom, HU16 5JQ
- Novartis Investigative Site
-
Edinburgh, United Kingdom, EH4 2XU
- Novartis Investigative Site
-
London, United Kingdom, EC1A 7BE
- Novartis Investigative Site
-
London, United Kingdom, W12 0HS
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Confirmed diagnosis of chronic phase Ph+ CML
- Previous first-line treatment with imatinib for a minimum of 2 years;
- Patient in complete cytogenetic response;
Key Exclusion Criteria:
- Previous achievement of MR4.0 at study entry;
- Previous treatment with other target cells inhibitors other than imatinib;
- Patients with any history of detectable atypical Leukemia transcripts or patients with detectable atypical leukemia transcripts at screening;
- Previous anticancer agents for Chronic myeloid leukemia other than imatinib except for cytoreduction;
- Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol;
- History of other active malignancies within the 5 years prior to study entry with the exception of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively;
- Patients who have not recovered from prior surgery;
- Treatment with other investigational agents within 4 weeks of Day 1;
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug
Other inclusion/exclusion criteria might apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nilotinib 24-month treatment
Participants were treated with nilotinib 300mg BID for 24 months and, thereafter, entered the 36-month TFR phase
|
Participants received a daily oral nilotinib dose of 300 mg BID, given as two 150 mg capsules BID.
Other Names:
|
Experimental: Nilotinib 36-month treatment
Participants were treated with nilotinib 300mg BID for 36 months and, thereafter, entered the 24-month TFR phase
|
Participants received a daily oral nilotinib dose of 300 mg BID, given as two 150 mg capsules BID.
Other Names:
|
Experimental: Not randomized
Participants were treated with nolotinib 300mg BID for 24 months, but did not achieve a sustained molecular response after 24 months of treatment.
|
Participants received a daily oral nilotinib dose of 300 mg BID, given as two 150 mg capsules BID.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Who Remained in Treatment Free Remission (TFR) Without Molecular Relapse 12 Months After Entering the TFR Phase
Time Frame: 12 months after entering the TFR phase, which is after 36 months from study treatment start for Nilotinib 24-month treatment arm and after 48 months from study treatment start for Nilotinib 36-month treatment arm
|
Number of participants who remained in TFR (≥molecular response (MR) 4.0) without molecular relapse 12 months after entering the TFR phase (without re-starting nilotinib therapy) divided by the number of participants who entered the TFR phase and multiplied by 100. Molecular relapse during TFR is defined as the loss of major molecular response (MMR), or the confirmed loss of MR4.0 (defined by 3 consecutive tests less than MR4.0 assessed at 3 consecutive visits during TFR phase). Participants dropping out early from the study during the TFR phase were considered as unsuccessful TFR. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL. MR4.0 is defined as either detectable disease≤0.01% BCR-ABL or undetectable disease in cDNA with≥10,000 ABL transcripts |
12 months after entering the TFR phase, which is after 36 months from study treatment start for Nilotinib 24-month treatment arm and after 48 months from study treatment start for Nilotinib 36-month treatment arm
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative Incidence of MMR During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry
Time Frame: From baseline up to 24 months after study treatment start
|
Number of participants who were in MMR during pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL. |
From baseline up to 24 months after study treatment start
|
Cumulative Incidence of MMR During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry
Time Frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start
|
Number of participants who were in MMR during post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL. |
From randomization (month 24 after study treatment start) up to 36 months after study treatment start
|
Cumulative Incidence of MR4.0 During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry
Time Frame: From baseline up to 24 months after study treatment start
|
Number of participants who were in MR4.0 during the pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL) |
From baseline up to 24 months after study treatment start
|
Cumulative Incidence of MR4.0 During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry
Time Frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start
|
Number of participants who were in MR4.0 during the post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL) |
From randomization (month 24 after study treatment start) up to 36 months after study treatment start
|
Cumulative Incidence of MR4.5 During the Pre-randomization Induction/Consolidation Phase Among Participants Without That Response at Study Entry
Time Frame: From baseline up to 24 months after study treatment start
|
Number of participants who were in MR4.5 during the pre-randomization induction/consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL) |
From baseline up to 24 months after study treatment start
|
Cumulative Incidence of MR4.5 During the Post-randomization Consolidation Phase Among Participants Without That Response at Study Entry
Time Frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start
|
Number of participants who were in MR4.5 during the post-randomization consolidation phase divided by the number of participants without that response at baseline and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL) |
From randomization (month 24 after study treatment start) up to 36 months after study treatment start
|
Cumulative Incidence of MMR During the Pre-randomization Induction/Consolidation Phase
Time Frame: From baseline up to 24 months after study treatment start
|
Number of participants who were in MMR during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL. |
From baseline up to 24 months after study treatment start
|
Cumulative Incidence of MMR During the Post-randomization Consolidation Phase
Time Frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start
|
Number of participants who were in MMR during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL. |
From randomization (month 24 after study treatment start) up to 36 months after study treatment start
|
Cumulative Incidence of MR4.0 During the Pre-randomization Induction/Consolidation Phase
Time Frame: From baseline up to 24 months after study treatment start
|
Number of participants who were in MR4.0 during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL) |
From baseline up to 24 months after study treatment start
|
Cumulative Incidence of MR4.0 During the Post-randomization Consolidation Phase
Time Frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start
|
Number of participants who were in MR4.0 during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL) |
From randomization (month 24 after study treatment start) up to 36 months after study treatment start
|
Cumulative Incidence of MR4.5 During the Pre-randomization Induction/Consolidation Phase
Time Frame: From baseline up to 24 months after study treatment start
|
Number of participants who were in MR4.5 during the pre-randomization induction/consolidation phase divided by the number of enrolled participants and multiplied by 100. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL) |
From baseline up to 24 months after study treatment start
|
Cumulative Incidence of MR4.5 During the Post-randomization Consolidation Phase
Time Frame: From randomization (month 24 after study treatment start) up to 36 months after study treatment start
|
Number of participants who were in MR4.5 during the post-randomization consolidation phase divided by the number of enrolled participants and multiplied by 100. Post-randomization consolidation phase corresponded to the 12-month additional treatment (after randomization) for Nilotinib 36-month treatment arm. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL) |
From randomization (month 24 after study treatment start) up to 36 months after study treatment start
|
Percentage of Participants Who Were in MMR During TFR Phase
Time Frame: From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
|
Number of participants who were in MMR at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1% BCR-ABL. |
From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
|
Percentage of Participants Who Were in MR4.0 During the TFR Phase
Time Frame: From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotininb 36-months treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-months treatment arm
|
Number of participants who were in MR4.0 at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.0 is defined as either detectable disease ≤0.01% BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL) |
From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotininb 36-months treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-months treatment arm
|
Percentage of Participants Who Were in MR4.5 During the TFR Phase
Time Frame: From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotininb 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
|
Number of participants who were in MR4.5 at selected timepoints divided by the number of participants in the TFR phase and multiplied by 100. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. Confidence intervals were calculated based on the Exact Clopper-Pearson method. MR4.5 is defined as either detectable disease ≤ 0.0032% BCR-ABL IS; or undetectable disease within cDNA with ≥ 32,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL) |
From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotininb 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
|
BCR-ABL Ratio (Expressed as a Percentage) During the Induction/Consolidation Phase
Time Frame: From baseline up to 24 months after study treatment start for Nilotinib 24-month treatment arm and Not randomized participants; and up to 36 months after study treatment start for Nilotinib 36-month treatment arm.
|
BCR-ABL transcript ratio by international scale (IS) (expressed as a percentage) during the induction/consolidation phase.
Participants randomized to Nilotinib 36-month treatment arm had 12-month additional consolidation phase (post-randomization).
|
From baseline up to 24 months after study treatment start for Nilotinib 24-month treatment arm and Not randomized participants; and up to 36 months after study treatment start for Nilotinib 36-month treatment arm.
|
BCR-ABL Ratio (Expressed as a Percentage) During the TFR Phase
Time Frame: From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
|
BCR-ABL/control gene (ABL) transcript ratio by international scale (IS) (expressed as a percentage) during the TFR phase. BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. |
From Month 1 after entering TFR phase up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
|
BCR-ABL Ratio (Expressed as a Percentage) During the Nilotinib Re-treatment Phase
Time Frame: From Day 1 after entering the re-treatment phase up to 24 months after entering re-treatment phase for Nilotinib 36-month treatment arm and 36 months after entering the re-treatment phase for Nilotinib 24-month treatment arm
|
BCR-ABL/control gene (ABL) transcript ratio by international scale (IS) (expressed as a percentage) during the nilotinib re-treatment phase.
BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes.
|
From Day 1 after entering the re-treatment phase up to 24 months after entering re-treatment phase for Nilotinib 36-month treatment arm and 36 months after entering the re-treatment phase for Nilotinib 24-month treatment arm
|
Progression-free Survival (PFS) During the TFR Phase of the Study.
Time Frame: From the start of the TFR phase to progression to AP/BC or death up to 24 months after entering TFR phase for Nilotininb 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
|
PFS is defined as the time from the date of start of the nilotinib TFR phase to the date of acelerated phase/blast crisis (AP/BC) or death, whichever came first. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotini 24-month treatment arm had a maximum of 36 months of TFR phase. Patients not known to have recurred or died on or before the cut-off date for PFS analysis were censored at the date of their last assessment (cytogenetic, hematology or extramedullary) for patients who were on study, and at the date of last contact for patients who were in follow-up. |
From the start of the TFR phase to progression to AP/BC or death up to 24 months after entering TFR phase for Nilotininb 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
|
Treatment -Free Survival (TFS) During the TFR Phase of the Study
Time Frame: From the start of the TFR phase to the date of occurrence of treatment-free survival event, up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
|
TFS is defined as the time from the start of the TFR phase to the date of the earliest of the following: loss of MMR, confirmed loss of MR4.0,re-start of nilotinib treatment, progression to AP/BC, or death from any cause. Patients not known to have had any of the events on or before the cut-off date were censored at the earlier of the date of their last assessment for patients who were still on study and the date of last contact for patients who were in follow-up. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotinib 24-month treatment arm had a maximum of 36 months of TFR phase. MMR is defined as ≥3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤0.1%BCR-ABL. MR4.0 is defined as either detectable disease ≤0.01%BCR-ABL IS or undetectable disease in cDNA with ≥10,000 ABL transcripts (numbers of ABL transcripts in the same volume of cDNA used to test for BCR-ABL) |
From the start of the TFR phase to the date of occurrence of treatment-free survival event, up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
|
Overall Survival (OS) Rate During the TFR Phase of the Study.
Time Frame: From the start of the TFR phase to death due to any cause, assessed up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
|
OS is defined as the time from start of the TFR phase to the time of death due to any cause. Participants randomized in Nilotinib 36-month treatment arm had a maximum of 24 months of TFR phase, whereas participants randomized in Nilotini 24-month treatment arm had a maximum of 36 months of TFR phase. For participants without any event on or before the cut-off date, survival time will be censored at the date of their last assessment for patients who are still on study, and at the date of last contact for patients who are in follow-up. |
From the start of the TFR phase to death due to any cause, assessed up to 24 months after entering TFR phase for Nilotinib 36-month treatment arm and up to 36 months after entering TFR phase for Nilotinib 24-month treatment arm
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAMN107AIC05
- 2012-005124-15 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia (CML) | Blast Phase Chronic Myelogenous Leukemia (CML) | Chronic Phase Phase Chronic Myelogenous Leukemia (CML) | Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)United States
-
Novartis PharmaceuticalsTerminatedCML | Philadelphia Chromosome Positive (Ph+) | Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough LevelsUnited States
-
UNC Lineberger Comprehensive Cancer CenterCompletedChronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | CML - Philadelphia Chromosome | CML (Chronic Myelogenous LeukemiaUnited States
-
Merck Sharp & Dohme LLCTerminatedBlast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML) | Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL)
-
Children's Oncology GroupPfizer; Erasmus Medical Center; Dutch Childhood Oncology Group; Innovative Therapies...Active, not recruitingAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Blastic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive CMLUnited States
-
Il-Yang Pharm. Co., Ltd.RecruitingChronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | CML, Refractory | CML - Philadelphia ChromosomeTurkey, Korea, Republic of, Russian Federation, Ukraine
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Astex Pharmaceuticals, Inc.RecruitingChronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive | BCR-ABL1 Positive Chronic Myelogenous Leukemia | BCR-ABL1 PositiveUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous LeukemiaUnited States
-
Novartis PharmaceuticalsCompletedPhiladelphia Chromosome Positive | Chronic Myelogenous Leukemia in Chronic PhaseJapan
Clinical Trials on Nilotinib
-
Niguarda HospitalCompletedLeukemia, Myeloid, Chronic-PhaseItaly
-
Novartis PharmaceuticalsTerminatedPulmonary Arterial HypertensionSwitzerland, United States, Germany, Singapore, Korea, Republic of, Canada
-
Georgetown UniversityUnknownParkinson Disease | Parkinsons Disease With DementiaUnited States
-
XSpray MicroparticlesCompleted
-
KeifeRx, LLCWorldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries...Not yet recruiting
-
Shenzhen Second People's HospitalDongguan People's Hospital; Zhongshan People's Hospital, Guangdong, China; The... and other collaboratorsRecruitingChronic Myeloid Leukemia, Chronic Phase | NilotinibChina
-
Andrew J. Wagner, MD, PhDMassachusetts General Hospital; Novartis; Brigham and Women's HospitalActive, not recruitingTenosynovial Giant Cell Tumor | Pigmented Villonodular Synovitis | Diffuse-type Giant Cell TumorUnited States
-
Novartis PharmaceuticalsNo longer availableHypereosinophilic Syndrome (HES)
-
Novartis PharmaceuticalsNo longer availableAcute Lymphoblastic Leukemia (ALL)
-
Novartis PharmaceuticalsCompleted